Hasani F, Masrour M, Khamaki S, Jazi K, Hosseini S, Heidarpour H
J Cell Mol Med. 2025; 29(2):e70337.
PMID: 39855897
PMC: 11761000.
DOI: 10.1111/jcmm.70337.
Terashima T, Nio K, Koshikawa N, Ueno M, Toyama T, Miyazawa M
BJC Rep. 2025; 3(1):2.
PMID: 39809945
PMC: 11733115.
DOI: 10.1038/s44276-024-00116-z.
Miyashita Y, Ose N, Okami J, Takami K, Sakamaki Y, Ikeda N
Cureus. 2024; 16(11):e73689.
PMID: 39677194
PMC: 11646151.
DOI: 10.7759/cureus.73689.
Seto I, Yamaguchi H, Takagawa Y, Azami Y, Takayama K, Suzuki M
Adv Radiat Oncol. 2024; 9(10):101577.
PMID: 39309704
PMC: 11415529.
DOI: 10.1016/j.adro.2024.101577.
Flammia F, Fusco R, Triggiani S, Pellegrino G, Reginelli A, Simonetti I
Cancer Control. 2024; 31:10732748241263644.
PMID: 39293798
PMC: 11412216.
DOI: 10.1177/10732748241263644.
Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study.
Miki M, Masuda A, Takenaka M, Shiomi H, Iemoto T, Tsumura H
J Gastroenterol. 2024; 59(12):1133-1142.
PMID: 39283502
PMC: 11541273.
DOI: 10.1007/s00535-024-02149-0.
Potential of Carbohydrate Antigen 19-9 and Serum Apolipoprotein A2-Isoforms in the Diagnosis of Stage 0 and IA Pancreatic Cancer.
Hanada K, Shimizu A, Tsushima K, Kobayashi M
Diagnostics (Basel). 2024; 14(17).
PMID: 39272705
PMC: 11394136.
DOI: 10.3390/diagnostics14171920.
Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning.
Kawai M, Fukuda A, Otomo R, Obata S, Minaga K, Asada M
Br J Cancer. 2024; 131(7):1158-1168.
PMID: 39198617
PMC: 11442445.
DOI: 10.1038/s41416-024-02794-5.
Safety and feasibility of percutaneous abdominal lavage cytology screening (PACS) prior to surgical resection for pancreatic cancer.
Sugawara S, Sone M, Umino R, Ban D, Itou C, Kimura S
Abdom Radiol (NY). 2024; 49(12):4365-4372.
PMID: 39120716
DOI: 10.1007/s00261-024-04510-6.
Pancreatic cancer risk in diabetic patients using the Japanese Regional Insurance Claims.
Satoh T, Nakatani E, Ariyasu H, Kawaguchi S, Ohno K, Itoh H
Sci Rep. 2024; 14(1):16958.
PMID: 39043788
PMC: 11266625.
DOI: 10.1038/s41598-024-67505-9.
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
Shibuki T, Otsuka T, Shimokawa M, Nakazawa J, Arima S, Fukahori M
Sci Rep. 2024; 14(1):16906.
PMID: 39043707
PMC: 11266600.
DOI: 10.1038/s41598-024-65689-8.
Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer.
Kitago M, Endo Y, Aiura K, Takigawa Y, Tani N, Matsui J
Cancer Med. 2024; 13(14):e7459.
PMID: 39030993
PMC: 11258433.
DOI: 10.1002/cam4.7459.
Relationship between pancreatic resection volume and post-operative glucose intolerance in distal pancreatectomy: A retrospective study.
Ida K, Kobayashi S, Tsuchihashi A, Koizumi S, Otsubo T
Indian J Gastroenterol. 2024; .
PMID: 39012611
DOI: 10.1007/s12664-024-01592-4.
Utilizing bifurcated allogeneic vein grafts: a novel approach for preventing sinistral portal hypertension following pancreaticoduodenectomy. A 10-year before and after study.
Wang J, Lyu S, Cui S, Huang J, Wang H, Hu B
Int J Surg. 2024; 111(1):9-19.
PMID: 38995182
PMC: 11745578.
DOI: 10.1097/JS9.0000000000001944.
Early detection of pancreatic cancer.
Morera-Ocon F
World J Clin Cases. 2024; 12(17):2935-2938.
PMID: 38898835
PMC: 11185363.
DOI: 10.12998/wjcc.v12.i17.2935.
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Kodama T, Imajima T, Shimokawa M, Otsuka T, Kawahira M, Nakazawa J
Sci Rep. 2024; 14(1):12422.
PMID: 38816500
PMC: 11139902.
DOI: 10.1038/s41598-024-63172-y.
Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions.
Boekestijn B, Feshtali S, Vasen H, van Leerdam M, Bonsing B, Mieog J
Fam Cancer. 2024; 23(3):295-308.
PMID: 38733421
PMC: 11254973.
DOI: 10.1007/s10689-024-00394-z.
Rim Enhancement on Contrast-Enhanced CT as a Predictor of Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Yamaguchi T, Sofue K, Ueshima E, Sugiyama N, Yabe S, Ueno Y
Diagnostics (Basel). 2024; 14(8).
PMID: 38667428
PMC: 11048909.
DOI: 10.3390/diagnostics14080782.
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting.
Reshkin S, Cardone R, Koltai T
Cells. 2024; 13(7.
PMID: 38607041
PMC: 11011857.
DOI: 10.3390/cells13070602.
High-grade pancreatic intraepithelial neoplasia diagnosed based on changes in magnetic resonance cholangiopancreatography findings: A case report.
Furuya N, Yamaguchi A, Kato N, Sugata S, Hamada T, Mizumoto T
World J Clin Cases. 2024; 12(8):1487-1496.
PMID: 38576815
PMC: 10989451.
DOI: 10.12998/wjcc.v12.i8.1487.